United States Patent 9,636,332: Scope, Claims, Exclusivity and Patent Landscape for Suprachoroidal Triamcinolone

United States Patent No. 9,636,332 protects a method of treating uveitis by non-surgically delivering a triamcinolone formulation into the suprachoroidal space (SCS). Its broadest protection is a use claim directed to the treatment method, not to triamcinolone as a molecule, a formulation standing alone, or a microneedle device standing alone. The patent is commercially relevant to XIPERE, Clearside Biomedical's triamcinolone acetonide injectable suspension for suprachoroidal use.

The core claim requires four elements: treatment of uveitis in a human, triamcinolone in the administered formulation, non-surgical administration into the ocular SCS, and an effective amount. Dependent claims add acute posterior uveitis, reduced dose, increased posterior-segment retention, higher intraocular exposure, reduced systemic exposure, microneedle dimensions, particulate formulation characteristics, triamcinolone acetonide, and limited intraocular-pressure change.

What does United States Patent 9,636,332 protect?

The patent protects the clinical use of triamcinolone delivered to the SCS for treating uveitis. The practical claim center is the combination of drug, disease, route, and delivery method.

Claim group	Principal limitation	Commercial significance
Claims 1-12	SCS administration of triamcinolone for uveitis, with technical dependent limitations	Broadest technical coverage in the supplied claims
Claims 13-17	SCS administration of triamcinolone for uveitis, with fewer limitations	Broader method-of-use fallback claims
Claim 1	Requires non-surgical SCS administration and posterior-segment localization	Core claim for a commercial SCS procedure
Claim 3	Requires a lower effective dose than specified alternative routes	Comparative pharmacology limitation
Claim 7	Requires a 500-1,500 micrometer microneedle	Delivery-device limitation
Claim 8	Requires microparticles or nanoparticles	Formulation limitation
Claim 9	Specifies triamcinolone acetonide	Active-ingredient limitation
Claim 10	Requires intraocular pressure variation of no more than about 10%	Clinical-performance limitation
Claim 13	Requires only non-surgical SCS administration of triamcinolone for uveitis	Broad independent method claim

Claims 1 and 13 overlap substantially. Claim 1 includes the posterior-segment localization requirement. Claim 13 omits that limitation and therefore has potentially broader literal scope, subject to claim construction, validity, and the actual issued claim text.

How broad are the independent claims?

Claim 1

Claim 1 requires:

A human subject with uveitis.
An effective amount of a formulation comprising triamcinolone.
Non-surgical administration.
Administration to the SCS.
Flow away from the insertion site.
Substantial localization to the posterior segment.

The claim does not expressly require:

triamcinolone acetonide;
a particular concentration;
a particular volume;
a particular needle;
a microparticle or nanoparticle formulation;
a specific injection site;
a particular treatment schedule;
a specific degree of clinical improvement.

The terms "effective amount," "substantially localized," and "flows away from the insertion site" are functional and potentially fact-intensive. They increase the claim's ability to cover different formulations and delivery configurations, but they can also create infringement and validity disputes over measurement methods and claim boundaries.

Claim 13

Claim 13 is materially broader on its face. It requires non-surgical administration of a triamcinolone-containing formulation to the SCS to treat uveitis. It does not expressly require posterior-segment localization, reduced systemic exposure, enhanced intraocular concentration, a microneedle, or particulate drug.

A product or procedure that delivers triamcinolone into the SCS could fall within claim 13 even if the evidence does not establish every pharmacokinetic or localization feature recited in claim 1. Claims 14-17 narrow claim 13 by adding acute posterior uveitis, particulate formulations, triamcinolone acetonide, and a lower SCS dose relative to other administration routes.

What technical limitations matter most for infringement?

The strongest commercial limitations are the SCS route and the triamcinolone-uveitis combination. A competing therapy that uses the same active ingredient but delivers it intravitreally, topically, orally, systemically, or intracamerally would not literally practice the SCS administration limitation.

The principal infringement questions are:

Issue	Relevance
Is the drug delivered into the SCS?	Central route limitation in claims 1 and 13
Is the administration non-surgical?	Excludes surgical implantation or open surgical delivery if properly construed
Is triamcinolone present in the administered formulation?	Required by every independent claim
Is the patient being treated for uveitis?	Required disease and patient limitation
Is the amount therapeutically effective?	Requires a treatment response or evidence supporting therapeutic efficacy
Does the formulation localize to the posterior segment?	Required expressly by claim 1, but not claim 13
Is a 500-1,500 micrometer microneedle used?	Required only by claim 7
Are particles 2 micrometers or less at D50?	Required only by claim 12 through claim 8

The route limitation is likely to be more commercially important than the particle-size limitations. A competitor could attempt to design around claims 7, 8, and 12 by using a different delivery instrument or a non-particulate formulation. That strategy would not avoid claims 1 or 13 if the product still practices the required SCS triamcinolone method.

What formulations are protected by the patent?

The claims cover a formulation comprising triamcinolone. Dependent claims expressly cover:

triamcinolone acetonide;
suspensions of microparticles;
suspensions of nanoparticles;
microparticles with a D50 of 2 micrometers or less.

The patent therefore reaches more than one specific commercial formulation. Claim 1 does not require a suspension, and claim 9 does not require a particular particle morphology. Claim 8 is narrower because it requires microparticles or nanoparticles.

The formulation claims should be separated from the method claims:

Protection type	Present in supplied claims?	Scope
Composition of matter for triamcinolone	No	The molecule itself is not claimed
Standalone injectable formulation	No	No composition claim appears in the supplied claims
SCS delivery method	Yes	Core patent protection
Treatment of uveitis	Yes	Required therapeutic use
Microneedle geometry	Yes, dependent	500-1,500 micrometers
Particle-size distribution	Yes, dependent	D50 of 2 micrometers or less
Manufacturing process	No	No manufacturing steps appear
Device claim	No	The microneedle is claimed only as part of a treatment method

What is the scope of the microneedle claims?

Claim 7 requires conveying the formulation to the SCS through a microneedle having a length from about 500 to about 1,500 micrometers. The word "about" creates an expected tolerance issue. A device close to either endpoint could require construction based on the specification, prosecution history, measurement method, and ordinary meaning in the field.

Claim 7 does not require a particular:

needle diameter;
needle bevel;
injection angle;
insertion depth;
material;
manufacturer;
delivery pressure;
injection volume.

The claim is a method claim. It does not independently prevent manufacture or sale of a microneedle that could be used for a non-infringing purpose. Liability would depend on use, inducement, contributory infringement, or other applicable theories.

How do the pharmacokinetic claims affect patent strength?

Claims 3-6 and 11 add comparative performance limitations:

lower effective dose through SCS administration;
greater posterior-segment retention;
higher intraocular Cmax;
lower systemic exposure;
a dose no greater than 50% of the comparator-route dose.

These limitations are commercially valuable because they describe the intended pharmacological advantage of SCS delivery. They are also more difficult to enforce than route-based limitations because infringement may require comparative testing.

The principal evidentiary questions include:

Which comparator formulation and dose are used?
Are the alternative routes tested under equivalent conditions?
Is "effective amount" measured by clinical outcome, concentration, or both?
Is Cmax measured in aqueous humor, vitreous, retina, choroid, or another ocular compartment?
How is posterior-segment retention calculated?
Is the 50% comparison based on mass, concentration, exposure, or administered volume?

A generic or follow-on product might avoid a comparative claim by using an SCS dose that is not shown to be lower than an alternative-route dose. That strategy would not necessarily avoid claims 1 or 13.

What is the FDA and Orange Book status of Patent 9,636,332?

XIPERE, triamcinolone acetonide injectable suspension, received FDA approval in October 2021 for the treatment of macular edema associated with uveitis. The product is administered by suprachoroidal injection and uses the Clearside SCS Microinjector. The approved dose is 4 mg, delivered as 0.1 mL of a 40 mg/mL suspension.[1]

Patent 9,636,332 is associated with the XIPERE patent estate and is listed in FDA drug-patent resources for the product. The patent protects a treatment method broader than the approved indication because the claims recite treatment of uveitis generally, including acute posterior uveitis, while the FDA label specifies macular edema associated with uveitis.

Regulatory item	Status
Active ingredient	Triamcinolone acetonide
Product	XIPERE
Sponsor	Clearside Biomedical, Inc.
FDA pathway	New Drug Application
NDA	214324
Approval	October 2021
Delivery route	Suprachoroidal injection
Commercial dose	4 mg in 0.1 mL
Relevant patent	U.S. Patent 9,636,332
Patent category	Method of treatment and SCS delivery
Biosimilar pathway	Not applicable

The Orange Book listing does not mean every claim in the patent is necessarily infringed by the approved product. It identifies the patent as relevant to the approved drug under the FDA's patent-listing framework. The commercial product's label, administration procedure, and formulation determine which claims are most directly implicated.[2]

When does Patent 9,636,332 lose exclusivity?

The patent has a twenty-year term measured from the applicable nonprovisional filing date, subject to patent-term adjustment and any terminal disclaimer. Public patent records place the expected expiration in 2033. The exact enforceable date should be taken from the USPTO patent-term data rather than inferred solely from the issue date.[3]

Event	Date or period
Patent issue	May 2, 2017
Expected base term	2033
Relevant commercial exclusivity period	Through the enforceable patent expiration, subject to adjustment
FDA regulatory exclusivity	Separate from patent term
Small-molecule generic pathway	ANDA, with Paragraph IV or Section VIII strategy

Patent expiration does not automatically authorize every competing SCS triamcinolone product. Other patents may cover the formulation, delivery system, injector, manufacturing process, or additional approved uses. Conversely, expiration of this patent would remove a major method-of-use barrier but would not eliminate separate patent or regulatory constraints.

What Paragraph IV challenges and generic entry risks exist?

An ANDA applicant seeking approval for a generic version of an approved triamcinolone product could address listed patents through:

Paragraph IV certification, asserting that the patent is invalid, unenforceable, or not infringed;
a Section VIII statement, carving out patented uses from the proposed label;
a combination of label restriction and non-infringement arguments;
a later-filed ANDA after patent expiration.

The claim structure creates different generic-entry scenarios.

Entry scenario	Risk under Patent 9,636,332
Generic triamcinolone for topical or intravitreal use	Lower risk under these claims because the SCS limitation is absent
Generic XIPERE-equivalent SCS suspension	High method-of-use risk because it would likely practice claims 1 or 13
SCS formulation using triamcinolone but a different needle	Claims 1 and 13 may remain relevant
SCS steroid using a different active ingredient	No literal infringement of the triamcinolone limitation
SCS triamcinolone product for a non-uveitis indication	Depends on label, induced use, physician practice, and claim construction
Product launched after patent expiration	Patent-specific risk substantially reduced

A Section VIII carve-out could be difficult if the proposed product's only commercially meaningful use is SCS treatment of uveitis. A label that omits the patented use may still face induced-infringement arguments if promotional material, instructions, distribution practices, or foreseeable clinical use encourage the patented method.

Which companies are challenging Patent 9,636,332?

The supplied record identifies no specific Paragraph IV challenger or litigation party. FDA Orange Book listing alone does not establish that a Paragraph IV certification has been filed. Public litigation records should be reviewed for any later ANDA notification, Hatch-Waxman complaint, settlement, or consent judgment.

The principal commercial parties are:

Company	Role
Clearside Biomedical	Developer and sponsor associated with XIPERE
FDA	Regulator of the approved drug and Orange Book listings
Potential ANDA applicants	Generic companies seeking approval of an SCS triamcinolone product
Competing steroid developers	Developers of intravitreal, topical, implant, or alternative SCS corticosteroids

No biosimilar challenge is relevant because triamcinolone acetonide is a chemically synthesized small molecule, not a biologic subject to the biosimilar pathway.

What patent litigation affects the commercial landscape?

The principal litigation exposure is likely to arise from an ANDA applicant seeking to market a product equivalent to XIPERE before expiration of the relevant patent estate. A patent owner could assert:

direct infringement based on the applicant's proposed use;
induced infringement based on the proposed label or marketing;
contributory infringement in limited circumstances;
infringement of separate formulation, injector, or manufacturing patents.

The treatment-method nature of the claims creates a different enforcement profile from a composition patent. A generic manufacturer may argue that it does not directly administer the drug. The patent owner would generally need to rely on method-of-use theories directed to the proposed product's labeled or encouraged use and the conduct of physicians, providers, or other actors.

How strong is the patent estate?

Patent strength is mixed by claim type.

Claim type	Relative strength	Reason
Claims 1 and 13	High commercial relevance	Directly target the SCS triamcinolone treatment concept
Claim 9 and claim 16	Stronger factual fit for XIPERE	Identify triamcinolone acetonide specifically
Claim 7	Moderate	Covers a defined microneedle range but permits device design-around
Claims 8 and 12	Moderate to narrow	Depend on particle type and D50 measurement
Claims 3-6 and 11	Fact-intensive	Require comparative pharmacology and testing
Claim 10	Narrow	Requires a quantified intraocular-pressure limitation
Claims 2 and 14	Narrow disease subtype	Limited to acute posterior uveitis

The broadest claims are vulnerable to prior-art and enablement arguments if the specification does not adequately support the full range of triamcinolone formulations, SCS delivery methods, uveitis subtypes, and therapeutic outcomes. The narrower claims may be more defensible if supported by specific examples, but they cover fewer competing products.

How does this patent compare with competing corticosteroid estates?

Patent 9,636,332 differs from estates covering intravitreal implants and conventional injectable corticosteroids.

Product or technology	Active ingredient	Principal route	Relationship to Patent 9,636,332
XIPERE	Triamcinolone acetonide	Suprachoroidal	Directly aligned with the claimed method
Triesence	Triamcinolone acetonide	Intravitreal or other labeled ophthalmic use	Different route; generally outside the SCS limitation
Ozurdex	Dexamethasone	Intravitreal implant	Different active ingredient and route
Iluvien	Fluocinolone acetonide	Intravitreal implant	Different active ingredient and delivery system
Kenalog-type products	Triamcinolone acetonide	Various off-label ophthalmic uses	Route and indication determine risk
Alternative SCS steroids	Other corticosteroids	Suprachoroidal	Generally outside the triamcinolone limitation

The patent is strongest against an SCS triamcinolone product that treats uveitis and uses a label or procedure closely matching XIPERE. It is less relevant to intravitreal products, non-triamcinolone corticosteroids, and products that do not promote treatment of uveitis.

Key Takeaways

U.S. Patent 9,636,332 is a method-of-treatment patent centered on non-surgical SCS delivery of triamcinolone for uveitis.
Claims 1 and 13 are the principal commercial claims. Claim 13 omits several technical limitations found in claim 1.
The patent does not claim triamcinolone as a compound, a standalone formulation, or a microneedle device independently.
Dependent claims cover triamcinolone acetonide, particulate formulations, microneedle lengths of about 500-1,500 micrometers, particle D50 of 2 micrometers or less, and comparative pharmacokinetic advantages.
XIPERE is the principal commercial product implicated by the patent.
The expected patent-term endpoint is in 2033, subject to patent-term adjustment and the official USPTO calculation.
Generic risk is highest for an ANDA product labeled for SCS administration of triamcinolone to treat uveitis.
Biosimilar risk does not apply.
A different needle, formulation, or dose may avoid some dependent claims but may not avoid claims 1 or 13.
Separate formulation, injector, manufacturing, and method-of-use patents must be reviewed before treating expiration of Patent 9,636,332 as full freedom to operate.

FAQs About U.S. Patent 9,636,332

Does Patent 9,636,332 cover all triamcinolone eye injections?

No. The supplied claims require administration to the suprachoroidal space. Intravitreal, topical, intracameral, oral, or systemic administration generally does not satisfy that route limitation.

Does the patent cover XIPERE specifically?

Yes, XIPERE's active ingredient, indication, and suprachoroidal delivery method align closely with the claimed subject matter. The commercial product may also be covered by other patents.

Can a generic avoid the patent by using a different microneedle?

Possibly for claim 7, but not necessarily for claims 1 or 13. The independent claims do not require the 500-1,500 micrometer microneedle limitation.

Is a triamcinolone suspension with larger particles outside the patent?

It may avoid claims 8 and 12 if those claims' particle limitations are not met. It may remain within claims 1, 9, 13, or 16, which do not all require the same particle-size characteristics.

Does patent expiration eliminate FDA approval barriers?

No. Patent expiration and FDA approval are separate issues. A generic applicant still must satisfy the applicable ANDA requirements, demonstrate pharmaceutical equivalence or otherwise qualify under the relevant pathway, and address all listed patents and regulatory exclusivities.

References

U.S. Food and Drug Administration. (2021). XIPERE (triamcinolone acetonide injectable suspension) prescribing information. https://www.accessdata.fda.gov
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
United States Patent and Trademark Office. (n.d.). Patent term calculator and patent term adjustment information. https://www.uspto.gov/patents/laws/patent-term-adjustment
United States Patent and Trademark Office. (2017). U.S. Patent No. 9,636,332, methods of treating uveitis. https://patents.google.com/patent/US9636332B2/en
Clearside Biomedical, Inc. (2021). XIPERE approval and product information. https://clearsidebio.com

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bausch And Lomb Inc	XIPERE	triamcinolone acetonide	SUSPENSION;INJECTION	211950-001	Oct 22, 2021		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				TREATMENT OF MACULAR EDEMA ASSOCIATED WITH UVEITIS	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2013342275	⤷ Start Trial
Australia	2017272182	⤷ Start Trial
Brazil	112015010566	⤷ Start Trial
Canada	2890471	⤷ Start Trial
Canada	3121763	⤷ Start Trial
China	104884049	⤷ Start Trial
China	110893188	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,636,332

Which drugs does patent 9,636,332 protect, and when does it expire?

Summary for Patent: 9,636,332